Keratinocytes Present Staphylococcus aureus Enterotoxins and Promote Malignant and Nonmalignant T Cell Proliferation in Cutaneous T-Cell Lymphoma

被引:0
|
作者
Zeng, Ziao
Vadivel, Chella Krishna
Gluud, Maria
Namini, Martin R. J.
Yan, Lang
Ahmad, Sana
Hansen, Morten Bagge [2 ]
Coquet, Jonathan
Mustelin, Tomas
Koralov, Sergei B.
Bonefeld, Charlotte Menne
Woetmann, Anders
Geisler, Carsten
Guenova, Emmanuella
Kamstrup, Maria R. [3 ,4 ]
Litman, Thomas
Gjerdrum, Lise-Mette R.
Buus, Terkild B. [1 ]
Odum, Niels [1 ]
机构
[1] Univ Copenhagen, Dept Immunol & Microbiol, LEO Fdn, Skin Immunol Res Ctr, Maersk Tower 07-12,Blegdamsvej 3B, DK-2200 Copenhagen, Denmark
[2] State Univ Hosp, Dept Clin Immunol, Blood Bank, Rigshosp, Copenhagen, Denmark
[3] Bispebjerg & Frederiksberg Univ Hosp, Dept Dermatol, Copenhagen, Denmark
[4] Zealand Univ Hosp, Dept Pathol, Roskilde, Denmark
关键词
Cutaneous T -cell lymphoma; Keratinocyte; Staphylococcus aureus; ENDOTHELIAL GROWTH-FACTOR; MESSENGER-RNA EXPRESSION; NECROSIS-FACTOR-ALPHA; MYCOSIS-FUNGOIDES; INTERFERON-GAMMA; SEZARY-SYNDROME; HLA-DR; HISTOCOMPATIBILITY ANTIGENS; DIFFERENTIAL EXPRESSION; CYTOKINE PRODUCTION;
D O I
10.1016/j.jid.2024.04.018
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Cutaneous T-cell lymphoma is characterized by malignant T cells proliferating in a unique tumor microenvironment dominated by keratinocytes (KCs). Skin colonization and infection by Staphylococcus aureus are a common cause of morbidity and are suspected of fueling disease activity. In this study, we show that expression of HLA-DRs, high-affinity receptors for staphylococcal enterotoxins (SEs), by KCs correlates with IFN-y expression in the tumor microenvironment. Importantly, IFN-y induces HLA-DR, SE binding, and SE presentation by KCs to malignant T cells from patients with Se<acute accent>zary syndrome and malignant and nonmalignant T-cell lines derived from patients with Se<acute accent>zary syndrome and mycosis fungoides. Likewise, preincubation of KCs with supernatant from patient-derived SE-producing S aureus triggers proliferation in malignant T cells and cytokine release (including IL-2), when cultured with nonmalignant T cells. This is inhibited by pretreatment with engineered bacteriophage S aureus-specific endolysins. Furthermore, alteration in the HLA-DR-binding sites of SE type A and small interfering RNA- mediated knockdown of Jak3 and IL-2Ry block induction of malignant T-cell proliferation. In conclusion, we show that upon exposure to patient-derived S aureus and SE, KCs stimulate IL-2Ry/Jak3-dependent proliferation of malignant and nonmalignant T cells in an environment with nonmalignant T cells. These findings suggest that KCs in the tumor microenvironment play a key role in S aureus-mediated disease activity in cutaneous T-cell lymphoma.
引用
收藏
页码:2789 / 2804.e10
页数:26
相关论文
共 50 条
  • [31] Menus for Managing Patients With Cutaneous T-Cell Lymphoma
    Poligone, Brian
    Heald, Peter
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2012, 31 (01) : 25 - 32
  • [32] Recurrent Bacterial Infections in Cutaneous T-cell Lymphoma
    Sateesh, Bharadwaj Adithya
    Bhagat, Yash, V
    Thomas, Sneha E.
    Sood, Aseem
    Michael, Miriam B.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (01)
  • [33] Emerging drugs for the treatment of cutaneous T-cell lymphoma
    Cheng, Melissa
    Zain, Jasmine
    Rosen, Steven T.
    Querfeld, Christiane
    EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (01) : 45 - 54
  • [34] Skin Directed Therapy in Cutaneous T-Cell Lymphoma
    Tarabadkar, Erica S.
    Shinohara, Michi M.
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [35] Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
    Lech-Maranda, Ewa
    Robak, Ewa
    Robak, Tadeusz
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2011, 6 (01) : 70 - 93
  • [36] Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma
    Pelcovits, Ari
    Ollila, Thomas A.
    Olszewski, Adam J.
    CANCER MANAGEMENT AND RESEARCH, 2023, 15 : 989 - 998
  • [37] Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma
    Zhang, Ping
    Zhang, Mingzhi
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [38] Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
    Prince, H. Miles
    Newland, Kate M.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (06): : 625 - 634
  • [39] New and emerging therapies in cutaneous T-cell lymphoma
    Roccuzzo, Gabriele
    Macagno, Nicole
    Giordano, Silvia
    Fava, Paolo
    Quaglino, Pietro
    DERMATOLOGY REPORTS, 2025, 17 (01)
  • [40] CAUSES OF DEATH IN CUTANEOUS T-CELL LYMPHOMA PATIENTS
    Lebas, Eve
    Collins, Patrick
    Somja, Joan
    Nikkels, Arjen
    DERMATOLOGY, 2023, 239 (06) : 860 - 867